Study Reveals Potential Bone and Heart Risks for Transgender Youth on Hormonal Treatments
A recently released report has brought to light potential health risks associated with the use of puberty blockers and hormone treatments in transgender youth. This taxpayer-funded study, titled "The Impact of Early Medical Treatment in Transgender Youth," was obtained by the Oversight Project and shared with The Daily Signal. It indicates that these treatments could have lasting negative impacts on bone density and heart health, among other health issues.
The National Institutes of Health initially allocated a nine-year grant of up to $10 million for this study, which was conducted through the Children’s Hospital of Los Angeles and led by Dr. Johanna Olson-Kennedy, a specialist in gender-affirming care. The report has been long-awaited, as it was previously reported that Dr. Olson-Kennedy hesitated to publish the findings due to concerns that they might be misused.
The study involved nearly 100 children, some as young as 8, with participants receiving puberty blockers up to the age of 16 and hormone treatments up to the age of 20. One of the significant findings of the report is that youth undergoing puberty blockers exhibited lower baseline bone-mineral density compared to the general population. The report emphasizes that these youths already have lower calcium levels in their bones, a situation that may be exacerbated by reduced physical activity.
Neal Cornett, the Director of State Litigation at the Oversight Project, expressed concern over the implications of low bone density, stating that it could affect athletic performance and growth potential, putting individuals at risk for conditions similar to osteoporosis.
Additionally, the report outlines how gender-affirming hormones can lead to unfavorable changes in cholesterol levels, with a decrease in HDL, often referred to as the “good” cholesterol, and an increase in LDL, known as the “bad” cholesterol. Specifically, after two years of treatment, youth starting estrogen showed increases in HDL and decreases in LDL, while those on testosterone showed the opposite trends.
The report also highlights potential impacts on reproductive health and fertility, noting that an archive of tissue samples will be established for future research into the long-term effects of gender-affirming care. Among biological females prescribed testosterone, 6.5% developed elevated red blood cell concentrations, which can increase the risk of vascular events.
Overall, the findings of this report underscore the need for ongoing research and careful consideration of the health implications for transgender youth undergoing these medical treatments. The complexity of the subject and the potential for significant health impacts warrant a thorough review by experts in the field.




